Covetrus (NASDAQ:CVET) had its price target decreased by Raymond James from $45.00 to $21.00 in a research report sent to investors on Thursday, AnalystRatings.com reports. Raymond James currently has an outperform rating on the stock.
A number of other brokerages have also weighed in on CVET. Guggenheim started coverage on Covetrus in a research note on Thursday, May 23rd. They issued a neutral rating for the company. ValuEngine cut Covetrus from a buy rating to a hold rating in a report on Tuesday, August 13th. Zacks Investment Research cut Covetrus from a buy rating to a hold rating in a report on Wednesday, July 17th. Cleveland Research initiated coverage on Covetrus in a report on Friday, May 10th. They issued a hold rating on the stock. Finally, Stifel Nicolaus decreased their price target on Covetrus from $30.00 to $18.00 and set a hold rating on the stock in a report on Wednesday, August 14th. Six equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Covetrus currently has an average rating of Hold and an average target price of $25.75.
Shares of NASDAQ:CVET opened at $14.85 on Thursday. Covetrus has a twelve month low of $12.22 and a twelve month high of $43.83. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.74 and a quick ratio of 0.93. The firm has a fifty day simple moving average of $23.40.
Covetrus Company Profile
Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.